Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches

• Published in: 3 Biotech Vol. 11; no. 2; p. 47
• Main Authors: Saha, Ratnadeep, Ghosh, Pratik, Burra, V. L. S. Prasad
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2021; Springer Nature B.V
• Subjects: Agriculture; Antibodies; Antigens; Bioinformatics; Biomaterials; Biotechnology; Cancer Research; Cell-mediated immunity; Chemistry; Chemistry and Materials Science; Cloning; Computer applications; Coronaviruses; COVID-19; Design; Epitopes; Glycoproteins; Immune clearance; Immune response (humoral); Immune system; Immunogenicity; Lymphocytes B; Lymphocytes T; Original; Original Article; Pandemics; Peptides; Proteins; Severe acute respiratory syndrome coronavirus 2; Stem Cells; Vaccines; Viral diseases; COVID-19; Docking; In silico; Simulation; Multi-epitope
• ISSN: 2190-572X; 2190-5738
• DOI: 10.1007/s13205-020-02574-x

COVID-19 caused by SARS-CoV-2 was declared a global pandemic by WHO (World Health Organization) in March, 2020. Within 6 months, nearly 750,000 deaths are claimed by COVID-19 across the globe. This called for immediate social, scientific, technological, public and community interventions. Considering the severity of infection and the associated mortalities, global efforts are underway to develop preventive measures against SARS-CoV-2. Among the SARS-CoV-2 target proteins, Spike (S) glycoprotein (a.k.a S Protein) is the most studied target known to trigger strong host immune response. A detailed analysis of S protein-based epitopes enabled us to design a novel B-cell-derived T-cell Multi-epitope-based peptide (MEBP) vaccine candidate. This involved a systematic and comprehensive computational protocol consisting of prediction of dual-purpose epitopes and designing an MEBP vaccine construct. This was followed by 3D structure validation, MEBP complex interaction studies, in silico cloning and vaccine dose-based immune response simulation to evaluate the immunogenic potency of the vaccine construct. The dual-purpose epitope prediction protocol was designed such that the same epitope elicits both humoral and cellular immune response unlike the earlier designs. Further, the epitopes predicted were screened against stringent criteria to ensure selection of a potent candidate with maximum antigen coverage and best immune response. The vaccine dose-based immune response simulation studies revealed a rapid antigen clearance through antibody generation and elevated levels of cell-mediated immunity during repeated exposure of the vaccine. The favourable results of the analysis strongly indicate that the vaccine construct is indeed a potent vaccine candidate and ready to proceed to the next steps of experimental validation and efficacy studies.